Astragaloside IV inhibits palmitate-mediated oxidative stress and fibrosis in human glomerular mesangial cells via downregulation of CD36 expression

Pharmacol Rep. 2019 Apr;71(2):319-329. doi: 10.1016/j.pharep.2018.12.008. Epub 2018 Dec 21.

Abstract

Background: The increased influx of free fatty acids (FFAs) into the kidney is a risk factor for diabetes nephropathy (DN). In the present study we investigated the effects of astragaloside IV (AS-IV) on FFA-induced lipid accumulation, oxidative stress, and activation of TGF-β1 signaling in human glomerular mesangial cells (HMCs).

Methods: A DN model was induced in Sprague Dawley rats by the administration of a high-fat diet and streptozocin, and HMCs were stimulated with palmitate. Lipid accumulation and FFA uptake were detected using Oil Red O and BODIPY™ FL C16 staining, respectively. The expression levels of TGF-β1, p-Smad2/3, FN, Col4 A1, NOX4, p22phox, and CD36 were evaluated by western blotting or immunofluorescence/immunohistochemistry. The level of reactive oxygen species (ROS) was detected using 2',7'-dichlorofluorescein diacetate and dihydroethidium.

Results: Exposure to palmitate induced marked lipid accumulation in HMCs, whereas co-treatment with AS-IV significantly attenuated this phenomenon. Moreover, AS-IV suppressed palmitate-induced expression of TGF-β1, p-Smad2/3, FN, Col4 A1, NOX4, and p22phox, in addition to ROS production. Notably, AS-IV reduced the palmitate-induced expression of CD36 in HMCs and DN rats. Treatment of HMCs with the CD36 inhibitor, sulfo-N-succinimidyl oleate (SSO), significantly attenuated FFA uptake, oxidative stress, and fibrosis. Nevertheless, the combined use of SSO and AS-IV did not enhance the efficacy.

Conclusion: AS-IV inhibited palmitate-induced HMCs oxidative stress and fibrosis via the downregulation of CD36 expression, mediating FFA uptake and lipid accumulation.

Keywords: Astragaloside IV; CD36; Fibrosis; Oxidative stress; Palmitate.

MeSH terms

  • Animals
  • CD36 Antigens / genetics*
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / pathology
  • Diet, High-Fat / adverse effects
  • Down-Regulation / drug effects
  • Fatty Acids, Nonesterified / metabolism
  • Fibrosis / pathology
  • Humans
  • Male
  • Mesangial Cells / drug effects
  • Mesangial Cells / pathology
  • Oxidative Stress / drug effects*
  • Palmitates / toxicity
  • Rats
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species / metabolism
  • Saponins / pharmacology*
  • Transforming Growth Factor beta1 / metabolism
  • Triterpenes / pharmacology*

Substances

  • CD36 Antigens
  • Fatty Acids, Nonesterified
  • Palmitates
  • Reactive Oxygen Species
  • Saponins
  • TGFB1 protein, human
  • Transforming Growth Factor beta1
  • Triterpenes
  • astragaloside A